Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

#4386

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Aim(s): The main goal is to compare the indications, efficacy and toxicity of these treatments in patients treated outside clinical trials.

Materials and methods: Retrospective study of patients with NENs treated at Vall d’Hebron Hospital under STZ and 5-Fluroacil (STZ-5FU) or TEM and capecitabine (CAPTEM) outside of a clinical trial in 2016-2024. A descriptive statistical analysis was done, the independence of the observed frequencies was evaluated using χ2 test and progression-free survival (PFS) was calculated using the Kaplan-Meier method.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,